Wed Jan 19, 2022 – 8:04 am ESTWed Jan 19, 2022 – 9:09 am EST
(LifeSiteNews) — A genetic testing company is being investigated after it was scrutinized in a New York Times article demonstrating that prenatal tests for a set of rare genetic disorders yield about 85 percent false positives.
Following the report on microdeletion false positives, test maker Natera’s stock dropped “as much as 3.5%,” thereby “injuring investors,” according to Frank R. Cruz’s legal practice, which announced shortly afterward that it is investigating Natera on behalf of investors “concerning possible violations of federal securities laws.”
The Securities Act of 1933 is designed in large part to “prohibit deceit, misrepresentations, and other fraud in the sale of securities.”
On January 1, along with a general report of astronomically high false positives for genetic microdeletion disorders, The New York Times also indicated that a study from Natera suggested there were three times as many false positives as actual detected cases of DiGeorge Syndrome, contrary to Natera’s stated claim that the number of false positives were equal to actual cases.
The average rate of 85 percent false positives for microdeletion genetic disorders was the outcome of a combination of studies from several different diagnostic labs as well as several studies involving
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Christian Journal or its editors
